Amgen's dazodalibep meets primary endpoint in Sjögren's Phase 3 trial

September 22, 2026 9:02 AM

Amgen (NASDAQ: AMGN) announced that its Phase 3 OASIZ 301 study evaluating dazodalibep in adults with moderate-to-severe systemic Sjögren's disease ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found